Immunotherapy

Immunotherapy is a process in which the immune system is enhanced, induced, or suppressed in order to maximize the body’s ability to remove disease on its own, without interference from harmful drugs. In cancer, immunotherapy refers to the process through which the body’s immune system is trained to remove tumor cells. This approach is also known as Biologic Therapy.

Antibodies and the Immune System

The immune system is a network of specialized cells that defend the body against "foreign" invaders including bacteria, viruses, and parasites. Antibodies are proteins that serve as cell “tags” to help the immune system. Each antibody is designed to bind to one specific type of antigen. Antigens are cell markers that help identify a specific type of cell. When an antibody binds to an antigen, it marks it for destruction by the body’s immune cells (B-cells and Natural Killer cells).

For example, a virus will produce a specific type of antigen. This antigen will bind to a specific antibody in the system. Any immune cells that come in contact with that antibody will recognize the virus as an intruder and destroy it.

Monoclonal Antibodies

Monoclonal antibodies (MABs or MOABs) work on cancer cells in the same way natural antibodies work, by identifying and binding to the target cells. They then alert other cells in the immune system to the presence of the cancer cells. MABs are specific for a particular antigen - one designed for a B-cell lymphoma will not work on cells for ovarian cancer cells for example. Newer treatments such as Zevalin® combine radioummunotherapy with monoclonal antibody therapy. This treatment is gaining recognition due to its effectiveness and short treatment duration.

Vaccines

Vaccines are another method used to stimulate an immune response, though research is still being conducted. Researchers have harvested special immune cells, called dendritic cells, from patients. Dendritic cells copy antigens and present them to the immune system. When a lymphocyte (B-cell or T-cell) “learns” about an antigen from a dendritic cell, it can then go and destroy cells with similar antigens.

Scientists expose dendritic cells to high levels of antigens produced by cancerous cells, so they become primed to attack tumors. These primed cells can then be injected into patients for use in targeting and destroying cancer.

T-Cell Immunotherapy

T-Cell Immunotherapy is similar to vaccination in that immune cells are primed to attack tumors. T-cells are harvested and primed to attack cancer cells. They are then injected directly into tumors.

Clinical Trials

Research in this field is ongoing. Talk to your medical team about the latest advances in this field. Clinical trials are ongoing in many places.

Follow this link to identify a conveniently located cancer treatment center and begin the process of enrollment.

Related Reading

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap